CN108610379B - 锝-99m标记环丙沙星黄原酸盐配合物及其制备方法和应用 - Google Patents
锝-99m标记环丙沙星黄原酸盐配合物及其制备方法和应用 Download PDFInfo
- Publication number
- CN108610379B CN108610379B CN201611143632.9A CN201611143632A CN108610379B CN 108610379 B CN108610379 B CN 108610379B CN 201611143632 A CN201611143632 A CN 201611143632A CN 108610379 B CN108610379 B CN 108610379B
- Authority
- CN
- China
- Prior art keywords
- tcn
- cpf2xt
- complex
- inflammation
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 title claims abstract description 42
- 229960003405 ciprofloxacin Drugs 0.000 title claims abstract description 25
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- ZOOODBUHSVUZEM-UHFFFAOYSA-N ethoxymethanedithioic acid Chemical compound CCOC(S)=S ZOOODBUHSVUZEM-UHFFFAOYSA-N 0.000 title claims abstract description 11
- 239000012991 xanthate Substances 0.000 title claims abstract description 11
- GKLVYJBZJHMRIY-OUBTZVSYSA-N Technetium-99 Chemical compound [99Tc] GKLVYJBZJHMRIY-OUBTZVSYSA-N 0.000 title description 5
- 229940056501 technetium 99m Drugs 0.000 title description 5
- 238000010668 complexation reaction Methods 0.000 title description 2
- 206010061218 Inflammation Diseases 0.000 claims abstract description 52
- 230000004054 inflammatory process Effects 0.000 claims abstract description 52
- 230000001580 bacterial effect Effects 0.000 claims abstract description 28
- 150000001875 compounds Chemical class 0.000 claims abstract description 12
- 239000003446 ligand Substances 0.000 claims abstract description 12
- 239000012216 imaging agent Substances 0.000 claims abstract description 8
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 32
- QGJOPFRUJISHPQ-UHFFFAOYSA-N Carbon disulfide Chemical compound S=C=S QGJOPFRUJISHPQ-UHFFFAOYSA-N 0.000 claims description 21
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene chloride Substances ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 21
- 238000003756 stirring Methods 0.000 claims description 15
- 238000001035 drying Methods 0.000 claims description 13
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 12
- 238000006243 chemical reaction Methods 0.000 claims description 11
- 239000012074 organic phase Substances 0.000 claims description 11
- 238000002390 rotary evaporation Methods 0.000 claims description 11
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 9
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 9
- 239000007787 solid Substances 0.000 claims description 9
- HCOMFAYPHBFMKU-UHFFFAOYSA-N butanedihydrazide Chemical compound NNC(=O)CCC(=O)NN HCOMFAYPHBFMKU-UHFFFAOYSA-N 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 claims description 7
- 239000008367 deionised water Substances 0.000 claims description 7
- 229910021641 deionized water Inorganic materials 0.000 claims description 7
- 238000001914 filtration Methods 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- 238000001816 cooling Methods 0.000 claims description 6
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 claims description 6
- 238000004108 freeze drying Methods 0.000 claims description 6
- 238000010438 heat treatment Methods 0.000 claims description 6
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 6
- 101100329225 Coprinopsis cinerea (strain Okayama-7 / 130 / ATCC MYA-4618 / FGSC 9003) cpf2 gene Proteins 0.000 claims description 5
- 238000004440 column chromatography Methods 0.000 claims description 5
- 238000003384 imaging method Methods 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 238000009206 nuclear medicine Methods 0.000 claims description 5
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 5
- 238000000746 purification Methods 0.000 claims description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 4
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 claims description 4
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 claims description 4
- 238000010992 reflux Methods 0.000 claims description 4
- 238000003786 synthesis reaction Methods 0.000 claims description 4
- LDLCZOVUSADOIV-UHFFFAOYSA-N 2-bromoethanol Chemical compound OCCBr LDLCZOVUSADOIV-UHFFFAOYSA-N 0.000 claims description 3
- 229910021626 Tin(II) chloride Inorganic materials 0.000 claims description 3
- JCNBTJXCJYBNOT-UHFFFAOYSA-N acetic acid;propane-1,2-diamine Chemical compound CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O.CC(N)CN JCNBTJXCJYBNOT-UHFFFAOYSA-N 0.000 claims description 3
- 230000015572 biosynthetic process Effects 0.000 claims description 3
- 239000005457 ice water Substances 0.000 claims description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M sodium bicarbonate Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- AXZWODMDQAVCJE-UHFFFAOYSA-L tin(II) chloride (anhydrous) Chemical compound [Cl-].[Cl-].[Sn+2] AXZWODMDQAVCJE-UHFFFAOYSA-L 0.000 claims description 3
- 239000003480 eluent Substances 0.000 claims description 2
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 claims description 2
- 238000000967 suction filtration Methods 0.000 claims description 2
- 238000001291 vacuum drying Methods 0.000 claims description 2
- 238000007710 freezing Methods 0.000 claims 1
- 238000010025 steaming Methods 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 abstract description 9
- 210000004369 blood Anatomy 0.000 abstract description 6
- 239000008280 blood Substances 0.000 abstract description 6
- 230000003285 pharmacodynamic effect Effects 0.000 abstract description 3
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 abstract description 3
- 239000000126 substance Substances 0.000 abstract description 3
- 125000004434 sulfur atom Chemical group 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 22
- 238000010172 mouse model Methods 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 238000005303 weighing Methods 0.000 description 5
- 241000191967 Staphylococcus aureus Species 0.000 description 4
- 230000029586 bacterial cell surface binding Effects 0.000 description 4
- KBPLFHHGFOOTCA-UHFFFAOYSA-N caprylic alcohol Natural products CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 241000282414 Homo sapiens Species 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- TVMXDCGIABBOFY-UHFFFAOYSA-N n-Octanol Natural products CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 2
- 238000005192 partition Methods 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000012217 radiopharmaceutical Substances 0.000 description 2
- 229940121896 radiopharmaceutical Drugs 0.000 description 2
- 230000002799 radiopharmaceutical effect Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- 239000001293 FEMA 3089 Substances 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- DKVNPHBNOWQYFE-UHFFFAOYSA-N carbamodithioic acid Chemical compound NC(S)=S DKVNPHBNOWQYFE-UHFFFAOYSA-N 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000006957 competitive inhibition Effects 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000012990 dithiocarbamate Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000004796 pathophysiological change Effects 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229910052713 technetium Inorganic materials 0.000 description 1
- GKLVYJBZJHMRIY-UHFFFAOYSA-N technetium atom Chemical compound [Tc] GKLVYJBZJHMRIY-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic Table
- C07F13/005—Compounds without a metal-carbon linkage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Optics & Photonics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种99mTcN‑CPF2XT配合物及其制备方法和应用,将含有喹诺酮类药效基团的环丙沙星转化为可与99mTc络合的环丙沙星黄原酸盐配体(CPF2XT),通过利用CPF2XT配体中的S原子与[99mTcN]2+核配位制备工艺,得到99mTcN‑CPF2XT配合物。该配合物为亲水性物质,放化纯度高、稳定性良好,制备简便,在细菌性炎症部位有较高的摄取与良好的滞留,炎症/肌肉、炎症/血比值好,可以区分细菌性炎症和非细菌性炎症,可作为新型细菌性炎症显像剂推广应用。
Description
技术领域:
本发明涉及放射性药物化学和临床核医学技术领域,具体说是涉及到一种锝-99m标记环丙沙星黄原酸盐配合物及其制备方法和应用。
背景技术:
炎症是一种常见而又重要的病理过程,而炎症反应与人体健康有着紧密的关系。尽管抗生素的出现使得炎症治疗有了很大的改善,但是随着现代医学的发展,各类化疗药剂使用,使得免疫力低下的病人越来越多。另外抗生素的大量使用也导致机体对这些药物的敏感程度降低,全球抗生素的滥用使得细菌的抗药性越来越强,甚至出现了超级细菌。时至今日,炎症依然成为全人类特别是发展中国家最常见的疾病之一,如何能早期有效区分细菌性炎症和非细菌炎症,让病人得到及时准确的治疗,成为目前迫切需要解决的问题。
核医学显像可以准确地定位病灶区域,反映炎症的病理生理变化,有助于发现病因从而针对性地制定治疗方案,灵敏度高,特异性强。而随着核医学显像的发展,制备和开发安全、有效的炎症显像剂,成为当前临床研究的迫切需要。锝-99m标记的环丙沙星(99mTc-ciprofloxacin)作为诊断炎症的放射性药物已经应用于临床,它可以区分细菌性炎症和非细菌性炎症,但其仍存在标记率不够高,特异性不高以及造成假阳性等不足,因此开发新型的该类炎症显像剂具有必要性。
本发明将锝-99m标记环丙沙星黄原酸盐配合物写为99mTcN核标记环丙沙星黄原酸盐配合物,将含有喹诺酮类药效基团的环丙沙星转化为可与99mTc络合的环丙沙星黄原酸盐配体(CPF2XT),利用CPF2XT配体中的S原子与[99mTcN]2+核配位制备稳定性好的99mTcN-CPF2XT配合物来用作新型炎症显像剂,具有重要的现实意义和广阔的临床应用前景,也是本领域面临的重要任务。
发明内容:
本发明的目的在于提供一种放化纯度高、稳定性良好,制备简便,应用于炎症显像领域的99mTcN核标记的环丙沙星黄原酸盐配合物,同时提供其制备方法。
为了达到上述目的,本发明采用以下技术方案:一种99mTcN核标记环丙沙星黄原酸盐配合物,分子通式写为一种99mTcN-CPF2XT配合物,其结构式如下:
99mTcN-CPF2XT配合物的制备方法如下:
1.配体CPF2XT的合成:
其合成路线为:
称取一定量的环丙沙星,溶解于无水甲醇中,缓慢加入对甲苯磺酸,搅拌至混合均匀并充分溶解;80℃下油浴加热反应12h,冷却至室温之后缓慢加入NaHCO3溶液,用CH2Cl2萃取,无水硫酸镁干燥有机相,过滤,旋蒸,得白色固体,为化合物I;
称取一定量化合物I,碳酸钾与溴乙醇,以乙腈作为溶剂,80℃油浴加热,搅拌回流反应12h;向反应体系加入适量去离子水溶解,用CH2Cl2萃取,合并有机相并用无水硫酸镁干燥,过滤,旋蒸,用CH2Cl2/CH3OH进行柱层析纯化,得白色固体,为化合物II;
称取一定量化合物II,溶于甲醇-水溶液中,室温下搅拌反应8h;旋蒸除去甲醇,并在剩余溶液中加入适量去离子水;缓慢滴加醋酸溶液,调节pH=5~6;用CH2Cl2萃取,合并有机相并用无水硫酸镁干燥,抽滤,旋蒸,用CH2Cl2/CH3OH进行柱层析纯化,得白色固体,为化合物III;
称取一定量化合物III,加入KOH,100℃条件下反应1h,之后在冰水浴冷却下,滴加二硫化碳(CS2),搅拌反应2h后,常温搅拌反应过夜;旋蒸除去多余CS2,冷冻干燥,用甲醇/无水乙醚重结晶,将产物放置于真空干燥箱干燥,得淡黄色固体,为化合物CPF2XT;
2.99mTcN-CPF2XT的制备:
取一支含有丁二酰二酰肼(SDH)、1,2-丙二胺四乙酸、SnCl2·2H2O的SDH冻干药盒,将适量新鲜99mTcO4 -淋洗液加入其中,充分摇匀,室温下反应20分钟得到[99mTcN]2+中间体溶液;将5mg CPF2XT配体加入到上述中间体溶液中,在室温下反应30分钟,得到99mTcN-CPF2XT配合物,其反应路线如下:
99mTcO4 -+SDHkit→[99mTcN]int 2+
[99mTcN]int 2++CPF2XT→99mTcN-CPF2XT。
本发明所述的化学合成试剂均是市售商品,来源广泛,容易获得,SDH冻干药盒已商品化,可以从北京师宏药物研制中心购买获得。
通过上述方法制备的99mTcN-CPF2XT配合物的放射化学纯度大于90%,其体外稳定性良好。该配合物在金黄色葡萄球菌致炎的小鼠模型中有较高的炎症摄取、炎症/肌肉以及炎症/血比值,可以成为一种新型的细菌性炎症显像剂。
将99mTcN-CPF2XT、99mTc-Ciprofloxacin和99mTcN核标记环丙沙星氨荒酸盐配合物(99mTcN-CPFXDTC)在细菌性炎症模型小鼠体内生物分布数据进行比较,结果如表1:
表1 99mTcN-CPF2XT、99mTcN-CPFXDTC和99mTc-Ciprofloxacin在注射后4h在细菌性炎症模型小鼠体内生物分布[(X±S)%ID/g]
以上结果表明,尽管99mTcN-CPF2XT在炎症中的摄取略低于99mTcN-CPFXDTC,但是其炎症/肌肉与炎症/血液比值均优于99mTcN-CPFXDTC,且其肝脏、肺的摄取明显低于99mTcN-CPFXDTC,降低了腹部的放射性摄取,有利于提高显像效果。与99mTc-Ciprofloxacin相比,99mTcN-CPF2XT有着更高的炎症摄取、炎症/肌肉与炎症/血液比值,表明99mTcN-CPF2XT作为一种性能优良的新型炎症显像剂具有广阔的应用前景。实验表明,99mTcN-CPF2XT配合物的鉴定及性能如下:
1.99mTcN-CPF2XT配合物的层析鉴定:
薄层层析色谱(TLC)鉴定:用聚酰胺薄膜作为支持体,分别用生理盐水和乙腈作展开剂,测定的层析结果见表2。
表2各组分的层析结果(Rf值)
由上述层析鉴定所测得的标记物的放射化学纯度大于90%。
2.99mTcN-CPF2XT配合物的脂水分配系数的测定
取10mL离心管,分别加入0.9mL PBS缓冲溶液(0.025mol/L),1.0mL正辛醇,0.1mL99mTcN-CPF2XT配合物溶液,于旋涡振荡器旋转混匀3min,之后在5000rpm下离心5min。分别取有机相和水相0.1mL,测定两相放射性计数,并计算其分配系数P(P=有机相的放射性活度/水相的放射性活度),测得logP=-0.12,说明99mTcN-CPF2XT是一种亲水性物质。
3.99mTcN-CPF2XT配合物的稳定性测定
将标记好的99mTcN-CPF2XT配合物分别在室温下和在37℃小鼠血清中放置不同时间(1、2、3、4、5、6小时)后测定其放射化学纯度,实验结果表明该配合物在室温下和在37℃小鼠血清中放置6小时后放射化学纯度均大于90%,说明其体外稳定性良好。
4.99mTcN-CPF2XT配合物的体外细菌竞争结合实验
在一离心试管中加入0.1mL约含金黄色葡萄球菌1×108个的PBS溶液(0.025mol/L,pH=7.4)、0.8mL生理盐水、0.1mL99mTcN-CPF2XT配合物溶液,作为实验组;离心试管中加入0.1mL不含细菌的PBS溶液(0.025mol/L,pH=7.4)、0.8mL生理盐水、0.1mL99mTcN-CPF2XT配合物溶液,作为空白组。将两组在37℃恒温箱中孵育1h后,离心,得到细菌沉淀与上清液。移取上清液,用1mL PBS溶液(0.025mol/L,pH=7.4)洗涤沉淀,并振荡使细菌再次悬浮,再次按上述条件离心,合并两次上清液。测定细菌沉淀、上清液、空白组离心管的放射性计数C。细菌结合率%=(C沉淀-C空白组)/(C沉淀-C空白组+C上清液)×100%,结果以平均结合率±标准偏差表示。为探究99mTcN-CPF2XT与细菌的结合是否具有特异性,选取环丙沙星标准品与制备的环丙沙星黄原酸盐(CPF2XT)配体为竞争药物,进行细菌结合的特异性竞争实验。将环丙沙星与CPF2XT分别配制成10mg/mL的溶液,各取0.8mL该溶液分别加至离心管中,并加入0.1mL约含金黄色葡萄球菌1×108个的PBS溶液(0.025mol/L,pH=7.4),37℃恒温孵育1h。之后加入0.1mL99mTcN-CPF2XT标记液,继续在37℃下恒温孵育1h,之后按上述方法计算体外细菌结合率。结果表明,99mTcN-CP2XT在加入环丙沙星和CPF2XT竞争抑制之后,其与细菌结合率分别降低了70.68%和86.00%,说明99mTcN-CP2XT配合物与细菌结合具有特异性。
5.99mTcN-CPF2XT配合物在炎症小鼠模型中的生物分布实验:
为验证99mTcN-CPF2XT是否能够区分细菌性炎症与非细菌性炎症,需要分别建立细菌性致炎和非细菌性致炎两种小鼠模型。细菌性致炎小鼠模型的建立:将0.1mL金黄色葡萄球菌(1×109/mL)注射到18~22g的昆明小鼠的左后腿肌肉部位,24h后取感染明显的模型小鼠进行生物分布实验。非细菌性炎症小鼠模型的建立:将0.1mL松节油注射到18~22g的昆明小鼠的左后腿肌肉部位,定期观察小鼠炎症生长情况,取致炎明显的模型小鼠进行生物分布实验。对上述两种模型小鼠分别经尾静脉注射0.1mL(约7.4×105Bq)配合物,于注射后0.5h、2h、4h断颈处死。取不同脏器、脓肿肌肉和对侧大腿肌肉称重,并在FM-2000型锝分析仪上测其放射性计数,每个时相的小白鼠数为5只。计算各组织的每克百分注射剂量(%ID/g)。结果见表3。
表3 99mTcN-CPF2XT配合物在不同炎症小鼠模型中的生物分布(n=5,%ID/g)
由以上结果可知,99mTcN-CPF2XT在炎症部位有较高的摄取和良好的滞留,炎症/肌肉、炎症/血比值好,且其在细菌性致炎模型的炎症摄取值更高,表明其可以区分细菌性炎症和非细菌性炎症。
本发明所述的99mTcN-CPF2XT配合物为亲水性物质,放化纯度高、稳定性良好,制备简便,在细菌性炎症部位有较高的摄取与良好的滞留,炎症/肌肉、炎症/血比值好,可以区分细菌性炎症和非细菌性炎症,可作为新型细菌性炎症显像剂推广应用,达到了发明目的。
具体实施方式:
下面通过实施例详述本发明:一种99mTcN-CPF2XT配合物,其结构式如下:
a.配体CPF2XT的合成
称取环丙沙星2.00g(6.00mmol),溶解于100mL无水甲醇,缓慢加入1.72g(8.90mmol)对甲苯磺酸,搅拌至混合均匀并充分溶解。80℃下油浴加热,搅拌回流反应12h,冷却至室温。缓慢加入NaHCO3溶液,用CH2Cl2萃取(100mL×3),合并有机相并用无水硫酸镁干燥,过滤,旋蒸,得白色固体,化合物I;
称取化合物I1.00 g(2.88mmol),K2CO31.20 g(8.64mmol)与溴乙醇0.72g(5.76mmol),加入50mL乙腈作溶剂,80℃油浴加热,搅拌回流反应12h;向反应体系加入适量去离子水溶解,用CH2Cl2萃取(100mL×3),合并有机相并用无水硫酸镁干燥,过滤,旋蒸。用CH2Cl2:CH3OH=9:1(v/v)进行柱层析纯化,得化合物II;
称取化合物II1.00 g(2.60mmol),LiOH·H2O 0.53g(12.80mmol)溶于40mL甲醇和10mL去离子水中,室温下搅拌反应8h;旋蒸除去甲醇,并在剩余溶液中加入适量去离子水;缓慢滴加醋酸溶液,调节pH=5~6;用CH2Cl2萃取(100mL×3),合并有机相并用无水硫酸镁干燥,抽滤,旋蒸。用CH2Cl2:CH3OH=9:1(v/v)进行柱层析纯化,得化合物III;
取化合物III0.50 g(1.33mmol),加入KOH 0.15g(2.66mmol)溶液,100℃条件下反应1h,冰水浴冷却至5℃以下,滴加约0.5mL二硫化碳(CS2),搅拌反应2h后,常温搅拌反应过夜;旋蒸除去多余CS2,冷冻干燥。用甲醇/无水乙醚重结晶,将产物放置于真空干燥箱干燥,得到化合物CPF2XT 0.21g。
1H-NMR(D2O,δ):8.41(s,1H),7.81(d,J=13.5Hz,1H),7.55(d,J=7.4Hz,1H),3.73(t,J=6.1Hz,2H),3.57(s,1H),3.25(s,4H),2.73(s,4H),2.61(t,J=6.1Hz,2H),1.32–1.22(m,2H),1.06(s,2H).
13C-NMR(D2O,δ):207.16,175.40,172.63,154.53,152.08,146.71,144.01,138.61,122.27,117.06,111.51,111.29,106.76,58.89,58.17,52.22,49.47,48.91,34.77,7.42
质谱MS(ES-):m/z=527.4
b.99mTcN-CPF2XT的制备
取一支含有丁二酰二酰肼(SDH)、1,2-丙二胺四乙酸、SnCl2·2H2O的SDH冻干药盒,将37~370MBq的99mTcO4 -淋洗液0.5-1mL加入其中,充分摇匀,室温下反应20分钟得到[99mTcN]2+中间体溶液;将5mg CPF2XT配体加入到上述中间体溶液中,在室温下反应30分钟,即得到所述的99mTcN-CPF2XT配合物。
上述所述99mTcN-CPF2XT配合物作为细菌性炎症显像剂在核医学领域的应用。
Claims (3)
2.一种权利要求1所述的99mTcN-CPF2XT配合物的制备方法,其工艺步骤如下:
A.配体CPF2XT的合成:
将环丙沙星,溶解于无水甲醇中,缓慢加入对甲苯磺酸,搅拌至混合均匀并充分溶解;80℃下油浴加热反应12h,冷却至室温之后缓慢加入NaHCO3溶液,用CH2Cl2萃取,合并有机相并用无水硫酸镁干燥,过滤,旋蒸,得到白色固体,为化合物I;
将化合物I,碳酸钾与溴乙醇,以乙腈作为溶剂,80℃油浴加热,搅拌回流反应12h;向反应体系加入去离子水溶解,用CH2Cl2萃取,合并有机相并用无水硫酸镁干燥,过滤,旋蒸;用CH2Cl2/CH3OH进行柱层析纯化,得到白色固体,为化合物II;
将化合物II和LiOH·H2O,溶于甲醇水溶液中,搅拌反应8h;旋蒸除去甲醇,并在剩余溶液中加入去离子水;缓慢滴加醋酸溶液,调节pH=5~6;用CH2Cl2萃取,合并有机相并用无水硫酸镁干燥,抽滤,旋蒸;用CH2Cl2/CH3OH进行柱层析纯化,得到白色固体,为化合物III;
将化合物III,加入KOH,100℃条件下反应1h,之后在冰水浴冷却下,滴加二硫化碳,搅拌反应2h后,常温搅拌反应过夜;旋蒸除去多余CS2,冷冻干燥;用甲醇/无水乙醚重结晶,将产物放置于真空干燥箱干燥,得淡黄色固体的配体CPF2XT化合物;其合成路线为:
b.99mTcN-CPF2XT的制备:
取一支含有丁二酰二酰肼、1,2-丙二胺四乙酸、SnCl2·2H2O的SDH冻干药盒,将37~370MBq的99mTcO4 -淋洗液0.5-1mL加入其中,充分摇匀,室温下反应20分钟得到[99mTcN]2+中间体溶液;将5mg CPF2XT配体加入到上述中间体溶液中,在室温下反应30分钟,得到所述的99mTcN-CPF2XT配合物。
3.如权利要求1所述的99mTcN-CPF2XT配合物在核医学显像领域制备细菌性炎症显像剂中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201611143632.9A CN108610379B (zh) | 2016-12-13 | 2016-12-13 | 锝-99m标记环丙沙星黄原酸盐配合物及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201611143632.9A CN108610379B (zh) | 2016-12-13 | 2016-12-13 | 锝-99m标记环丙沙星黄原酸盐配合物及其制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN108610379A CN108610379A (zh) | 2018-10-02 |
CN108610379B true CN108610379B (zh) | 2020-09-11 |
Family
ID=63643412
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201611143632.9A Active CN108610379B (zh) | 2016-12-13 | 2016-12-13 | 锝-99m标记环丙沙星黄原酸盐配合物及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108610379B (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101289466A (zh) * | 2008-05-09 | 2008-10-22 | 北京师范大学 | 99TcmN核标记环丙沙星氨荒酸盐配合物及制备方法和应用 |
CN101486734A (zh) * | 2009-02-17 | 2009-07-22 | 北京师范大学 | 99Tcm(CO)3环丙沙星氨荒酸盐配合物及制备方法和应用 |
CN101555229A (zh) * | 2009-05-21 | 2009-10-14 | 北京师范大学 | 99TcmO核标记硝基咪唑类黄原酸盐配合物及制备方法和应用 |
-
2016
- 2016-12-13 CN CN201611143632.9A patent/CN108610379B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101289466A (zh) * | 2008-05-09 | 2008-10-22 | 北京师范大学 | 99TcmN核标记环丙沙星氨荒酸盐配合物及制备方法和应用 |
CN101486734A (zh) * | 2009-02-17 | 2009-07-22 | 北京师范大学 | 99Tcm(CO)3环丙沙星氨荒酸盐配合物及制备方法和应用 |
CN101555229A (zh) * | 2009-05-21 | 2009-10-14 | 北京师范大学 | 99TcmO核标记硝基咪唑类黄原酸盐配合物及制备方法和应用 |
Non-Patent Citations (2)
Title |
---|
Kalme Sachin et al.,.Synthesis of N4’-[18F] Fluoroalkylated Ciprofloxacin as a Potential Bacterial Infection Imaging Agent for PET Study.《Bioconjugate Chem.》.2010, * |
翟君.氨荒酸、黄原酸及中性配体锑配合物的合成、表征及结构研究.《聊城大学硕士论文》.2008, * |
Also Published As
Publication number | Publication date |
---|---|
CN108610379A (zh) | 2018-10-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK175393B1 (da) | Bifunktionelle chelateringsmidler, komplekser deraf, antistof-konjugater omfattende komplekserne samt fremgangsmåde til fremstilling af chelateringsmidlerne | |
JP6770207B2 (ja) | 99mTc標識イソシアニド含有グルコース誘導体及びその調製方法と応用 | |
Ibrahim et al. | Synthesis and biological distribution of 99m Tc–norfloxacin complex, a novel agent for detecting sites of infection | |
Ono et al. | Development of novel β-amyloid probes based on 3, 5-diphenyl-1, 2, 4-oxadiazole | |
JPH03188048A (ja) | 放射性同位元素を錯化するためのキレート化剤及びその製法、その金属キレート、このキレートを含有する腫瘍の診断及び治療用薬剤 | |
CN112175025B (zh) | 一种含苯环的葡萄糖衍生物及其应用 | |
CN111138504B (zh) | 一种99mTc-CNPEDG配合物及其制备方法和应用 | |
CN111518137B (zh) | 锝-99m标记含异腈的氨基酸衍生物及制备方法和应用 | |
CN115010629B (zh) | 前列腺特异性膜抗原抑制剂、其核素标记物及制法和应用 | |
CN110183493B (zh) | 一种99m锝标记配合物及其在诊断非小细胞肺癌中的应用 | |
CN109320557B (zh) | 99mTc(CO)3核标记的含异腈的帕博西尼衍生物及制备方法和应用 | |
CN108610379B (zh) | 锝-99m标记环丙沙星黄原酸盐配合物及其制备方法和应用 | |
Motaleb et al. | Preparation and quality control of 99mTc-6-{[2-amino-2-(4-hydroxyphenyl)-acetyl] amino}-3, 3-dimethyl-7-oxo-4-thia-1-azabicyclo-heptane-2-carboxylic acid complex as a model for detecting sites of infection | |
US20240109929A1 (en) | Mannose derivative and application thereof | |
CN103497217A (zh) | 与Aβ斑块具有高亲和力的2-芳基苯并噻唑类化合物、其制备方法及应用 | |
CN114031652B (zh) | 一种含环己烷的葡萄糖衍生物及其应用 | |
CN101475595B (zh) | 99TcmN核标记硝基咪唑类黄原酸盐配合物及制备方法和应用 | |
CN114225057B (zh) | 一种锝-99m标记含异腈的UBI 29-41衍生物及制备方法和应用 | |
CN102827208B (zh) | 99mTcO核标记蛋氨酸氨荒酸盐配合物的制备方法和应用 | |
Shah et al. | 99m Tc (CO) 3-tosufloxacin dithiocarbamate complexation and radiobiological evaluation in male Wister rat model | |
CN101085787B (zh) | 锝-99m标记的二巯基丁二酸酯类配合物及其制备方法和应用 | |
CN114349801B (zh) | 一种锝-99m标记含异腈的铁草胺衍生物及制备方法和应用 | |
Shah et al. | Synthesis of 99m TcN-clinafloxacin dithiocarbamate complex and comparative radiobiological evaluation in Staphylococcus aureus infected mice | |
CN106008636B (zh) | 锝‑99m标记葡萄糖氨荒酸盐配合物及制备方法和应用 | |
Tsoukalas et al. | Ester-modified 99mTcO [SN (R) S/S] mixed ligand complexes: synthesis and preliminary evaluation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |